Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma

Jebar, Adel; Errington-Mais, Fiona; Vile, Richard G.; Selby, Peter J.; Melcher, Alan; Griffin, Stephen

doi:10.1099/vir.0.000098

Cited by 33 publications

(38 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent advances in genetically modified cancer-killing viruses have shown increasing promise both experimentally and clinically (see Aghi & Martuza, 2005;Jebar et al, 2015;Lawler, Speranza, Cho, & Chiocca, 2017;Prestwich et al, 2008;Russell, Peng, & Bell, 2012;Wang et al, 2016). Many naturally occurring viruses are being investigated for their use in cancer treatments, for example: Herpes Simplex Virus, adenovirus, measles, reovirus, Vesicular Stomatitis Virus (Russell et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Treating cancerous cells with viruses: insights from a minimal model for oncolytic virotherapy

Jenner

Coster

Kim

et al. 2018

Letters in Biomathematics

View full text Add to dashboard Cite

In recent years, interest in the capability of virus particles as a treatment for cancer has increased. In this work, we present a mathematical model embodying the interaction between tumour cells and virus particles engineered to infect and destroy cancerous tissue. To quantify the effectiveness of oncolytic virotherapy, we conduct a local stability analysis and bifurcation analysis of our model. In the absence of tumour growth or viral decay, the model predicts that oncolytic virotherapy will successfully eliminate the tumour cell population for a large proportion of initial conditions. In comparison, for growing tumours and decaying viral particles there are no stable equilibria in the model; however, oscillations emerge for certain regions in our parameter space. We investigate how the period and amplitude of oscillations depend on tumour growth and viral decay. We find that higher tumour replication rates result in longer periods between oscillations and lower amplitudes for uninfected tumour cells. From our analysis, we conclude that oncolytic viruses can reduce growing tumours into a stable oscillatory state, but are insufficient to completely eradicate them. We propose that it is only with the addition of other anti-cancer agents that tumour eradication may be achieved by oncolytic virus. ARTICLE HISTORY

show abstract

Section: Introductionmentioning

confidence: 99%

Treating cancerous cells with viruses: insights from a minimal model for oncolytic virotherapy

Jenner

Coster

Kim

et al. 2018

Letters in Biomathematics

View full text Add to dashboard Cite

show abstract

“…Although oncolytic virotherapy kills cancer cells more specifically, it has not been effective so far as a single therapy due to poor dissemination and limited ability to transduction within tumors [34]. At present, several clinical trials reported significantly enhanced antitumor activity when incorporating irradiation or chemotherapy to virotherapy [35][36][37][38][39]. Therefore, a detailed study is required to understand the interactions between viruses and chemotherapeutic agents to design more effective anticancer drugs [40].…”

Section: Discussionmentioning

confidence: 99%

Cisplatin Relocalizes RNA Binding Protein HuR and Enhances the Oncolytic Activity of E4orf6 Deleted Adenovirus

Habiba

Hossain

Yanagawa‐Matsuda

et al. 2020

Cancers

View full text Add to dashboard Cite

The combination of adenoviruses and chemotherapy agents is a novel approach for human cancer therapeutics. A meticulous analysis between adenovirus and chemotherapeutic agents can help to design an effective anticancer therapy. Human antigen R (HuR) is an RNA binding protein that binds to the AU-rich element (ARE) of specific mRNA and is involved in the export and stabilization of ARE-mRNA. Our recent report unveiled that the E4orf6 gene deleted oncolytic adenovirus (dl355) replicated for certain types of cancers where ARE-mRNA is stabilized. This study aimed to investigate whether a combined treatment of dl355 and Cis-diamminedichloroplatinum (CDDP) can have a synergistic cell-killing effect on cancer cells. We confirmed the effect of CDDP in nucleocytoplasmic HuR shuttling. In vitro and in vivo experiments showed the enhancement of cancer cell death by apoptosis induction and a significant reduction in tumor growth following combination treatment. These results suggested that combination therapy exerted a synergistic antitumor activity by upregulation of CDDP induced cytoplasmic HuR, which led to ARE mRNA stabilization and increased virus proliferation. Besides, the enhanced cell-killing effect was due to the activation of the intrinsic apoptotic pathway. Therefore, the combined treatment of CDDP and dl355 could represent a rational approach for cancer therapy.

show abstract

“…Nanomaterials designed for cancer therapy can be as diverse as micelles, dendrimers, inorganic NP, carbon NP and nanotubes, nanodiamonds, nanoemulsions, viral nanocarriers, peptide NP, solid lipid NP [15][16][17][18], etc., although most clinically available nanomaterials for human use are liposomes and polymer-based nanoformulations [11,12]. In fact, the first nanotechnology-based cancer drugs on the market was a pegylated liposome with the drug doxorubicin encapsulated (Doxil) [5], which was approved in 1995 by the Food and Drug Administration (FDA) for the treatment of AIDS-related…”

Section: Cancer Therapymentioning

confidence: 99%

Clinical advances of nanocarrier-based cancer therapy and diagnostics

Luque-Michel

Imbuluzqueta

Sebastián

et al. 2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Cancer is a leading cause of death worldwide and efficient new strategies are urgently needed to combat its high mortality and morbidity statistics. Fortunately, over the years, nanotechnology has evolved as a frontrunner in the areas of imaging, diagnostics and therapy, giving the possibility of monitoring, evaluating and individualizing cancer treatments in real-time. Areas covered: Polymer-based nanocarriers have been extensively studied to maximize cancer treatment efficacy and minimize the adverse effects of standard therapeutics. Regarding diagnosis, nanomaterials like quantum dots, iron oxide nanoparticles or gold nanoparticles have been developed to provide rapid, sensitive detection of cancer and, therefore, facilitate early treatment and monitoring of the disease. Therefore, multifunctional nanosystems with both imaging and therapy functionalities bring us a step closer to delivering precision/personalized medicine in the cancer setting. Expert opinion: There are multiple barriers for these new nanosystems to enter the clinic, but it is expected that in the near future, nanocarriers, together with new 'targeted drugs', could replace our current treatments and cancer could become a nonfatal disease with good recovery rates. Joint efforts between scientists, clinicians, the pharmaceutical industry and legislative bodies are needed to bring to fruition the application of nanosystems in the clinical management of cancer.

show abstract

Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma

Cited by 33 publications

References 157 publications

Treating cancerous cells with viruses: insights from a minimal model for oncolytic virotherapy

Treating cancerous cells with viruses: insights from a minimal model for oncolytic virotherapy

Cisplatin Relocalizes RNA Binding Protein HuR and Enhances the Oncolytic Activity of E4orf6 Deleted Adenovirus

Clinical advances of nanocarrier-based cancer therapy and diagnostics

Contact Info

Product

Resources

About